Healthy Volunteer Study of Sildenafil Effects Upon Vision

This study has been completed.

Sponsored by:	University of Cambridge
Information provided by:	University of Cambridge
ClinicalTrials.gov Identifier:	NCT00251784

Purpose

Patients sometimes report subjective visual effects when taking sildenafil. Our study set out to measure these in a controlled setting. Subjects were asked to detect patterns presented on a monitor screen.

Condition	Intervention	Phase
Blindness	Drug: Sildenafil	Phase IV

Drug Information available for: Sildenafil citrate Sildenafil

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Educational/Counseling/Training, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Official Title:	A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil

Further study details as provided by University of Cambridge:

Study Start Date:	February 2002
Estimated Study Completion Date:	June 2003

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria: male -

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00251784

Sponsors and Collaborators

University of Cambridge

Investigators

Principal Investigator:	Morris J Brown, MD	University of Cambridge
Study Director:	John Mollon, FRS	University of Cambridge

More Information

Study ID Numbers:	LREC 98/297
Study First Received:	November 9, 2005
Last Updated:	November 9, 2005
ClinicalTrials.gov Identifier:	NCT00251784
Health Authority:	United Kingdom: National Health Service

Study placed in the following topic categories:

Signs and Symptoms
Sensation Disorders
Vision Disorders
Eye Diseases
Neurologic Manifestations

Sildenafil
Healthy
Blindness
Vision, Low

Additional relevant MeSH terms:

Vasodilator Agents
Phosphodiesterase Inhibitors
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses

Nervous System Diseases
Enzyme Inhibitors
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009